Algernon Pharmaceuticals Inc logo

Algernon Pharmaceuticals Inc - Class A

XCNQ:AGN (Canada)   Class A
C$ 0.13 (+13.64%) May 10
At Loss
P/B:
1.95
Market Cap:
C$ 2.71M ($ 1.98M)
Enterprise V:
C$ 2.63M ($ 1.92M)
Volume:
31.00K
Avg Vol (2M):
39.95K
Also Trade In:
Volume:
31.00K
At Loss
Avg Vol (2M):
39.95K

Business Description

Description
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.26
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 63.13
9-Day RSI 59.38
14-Day RSI 57.85
6-1 Month Momentum % 33.33
12-1 Month Momentum % -60.78

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.04
Quick Ratio 0.04
Cash Ratio 0.03

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -33.7
Name Current Vs Industry Vs History
ROE % -190.5
ROA % -100.44
ROIC % -80.44
ROCE % -136.45

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 1.95
EV-to-EBIT -0.68
EV-to-EBITDA -0.69
EV-to-Forward-Revenue 29.71
EV-to-FCF -1.43
Earnings Yield (Greenblatt) % -147.06
FCF Yield % -68.02

Financials (Next Earnings Date:2024-07-31 Est.)

XCNQ:AGN's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Algernon Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil C$)
EPS (TTM) (C$) -0.42
Beta 1.29
Volatility % 79.34
14-Day RSI 57.85
14-Day ATR (C$) 0.01041
20-Day SMA (C$) 0.10975
12-1 Month Momentum % -60.78
52-Week Range (C$) 0.05 - 0.265
Shares Outstanding (Mil) 21.64

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Algernon Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Algernon Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(C$)
No Event Data

Algernon Pharmaceuticals Inc Frequently Asked Questions

What is Algernon Pharmaceuticals Inc(XCNQ:AGN)'s stock price today?
The current price of XCNQ:AGN is C$0.13. The 52 week high of XCNQ:AGN is C$0.27 and 52 week low is C$0.05.
When is next earnings date of Algernon Pharmaceuticals Inc(XCNQ:AGN)?
The next earnings date of Algernon Pharmaceuticals Inc(XCNQ:AGN) is 2024-07-31 Est..
Does Algernon Pharmaceuticals Inc(XCNQ:AGN) pay dividends? If so, how much?
Algernon Pharmaceuticals Inc(XCNQ:AGN) does not pay dividend.

Press Release

Subject Date
No Press Release